Safety of lornoxicam in G-6-PDH deficiency

Abstract Views: 726
PDF: 523
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Objective: To assess the safety of lornoxicam in subjects with G-6-PDH deficiency. Methods: Open controlled 2-week in vivo study on lornoxicam 8 mg bid in subjects with G-6-PDH deficiency suffering from rheumatic diseases. Results: In 8 male patients with the Mediterranean form of G-6-PDH deficiency (mean age ± SD, 54.3 years ± 7.2) lornoxicam showed no influence on red blood cells (RBC) survival curve. The RBC half-life was the same before and after two weeks of treatment. Conclusions: Lornoxicam caused no RBC damage and evidenced favourable safety in subjects with G-6-PDH deficiency, suffering from rheumatic diseases.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Perpignano, G., Cacace, E., Matulli, C., & Ruggiero, V. (2003). Safety of lornoxicam in G-6-PDH deficiency. Reumatismo, 55(1), 45–47. https://doi.org/10.4081/reumatismo.2003.45